Clinical Applications and Biological Effects of Interferons in Dermatology
Keywords:
Interferón, Citoquinas, Antiviral, Inmunomodulador, Antiproliferativo, Antiangiogénico, Antifibrótico., : interferón; citoquinas; antiviral; inmunomodulador; antiproliferativo; antiangiogénico, antifibrótico.Abstract
Interferons are among the most active biological substances, constituting a complex system of glycoproteins produced by different types of cells. They are classified within the group of cytokines and are grouped, according to the amino acid sequence of their protein structures, into three main classes: alpha, beta and gamma. Due to the natural activity they possess and their broad spectrum of action as antiviral, antiproliferative, antiangiogenic and antifibrotic immunomodulators, they are considered therapeutic pillars in various diseases.
Objetive: of this work is to highlight the most relevant characteristics of interferons and their application in some dermatological conditions.
Downloads
References
1. Walter MR. The Role of Structure in the Biology of Interferon Signaling. Front Immunol. 2020;11. DOI: https://doi.org/10.3389/fimmu.2020.606489
2. Isaacs A, Lindenmann J. Virus interference. I The interferon. Proc R Soc Lond B Biol Sci. 1957;147(927):258-67. DOI: https://doi.org/10.1098/rspb.1957.0048
3. Andrea M de, Ravera R, Gioia D, Gariglio M, Landolfo S. The interferon system: an overview. European Journal of Paediatric Neurology. 2002; 6:A41-6. DOI: https://doi.org/10.1053/ejpn.2002.0573
4. Kontsek P, Kontseková E. Forty years of interferon. Acta Virol. 1997 [acceso 20/09/2024];41(6):349-53. Disponible en: https://pubmed.ncbi.nlm.nih.gov/9607096/
5. Negishi H, Taniguchi T, Yanai H. The Interferon (IFN) Class of Cytokines and the IFN Regulatory Factor (IRF) Transcription Factor Family. Cold Spring Harb Perspect Biol. 2018;10(11):a028423. DOI: https://doi.org/10.1101/cshperspect.a028423
6. Capobianchi MR, Uleri E, Caglioti C, Dolei A. Type I IFN family members: Similarity, differences and interaction. Cytokine Growth Factor Rev. 2015;26(2):103-11. DOI: https://doi.org/10.1016/j.cytogfr.2014.10.011
7. Decker T, Müller M, Stockinger S. The Yin and Yang of type I interferon activity in bacterial infection. Nat Rev Immunol. 2005;5(9):675-87. DOI: https://doi.org/10.1038/nri1684
8. Matthews SJ, McCoy C. Peginterferon alfa-2a: A review of approved and investigational uses. Clin Ther. 2004;26(7):991-1025. DOI: https://doi.org/10.1016/s0149-2918(04)90173-7
9. Veja J, Alvarez A, Ventura K, Fernandez A, Nodal S. Tratamiento con HeberFERON® del carcinoma basocelular en la Atención Primaria de Salud en Cuba. Revista Cubana de Medicina General Integral. 2021 [acceso 20/09/2024];37(2). Disponible en: https://revmgi.sld.cu/index.php/mgi/article/view/1340
10. De Clercq E. Interferon and Its Inducers—A Never-Ending Story: “Old” and “New” Data in a New Perspective. J Infect Dis. 2006;194(Suppl_1):S19-26. DOI: https://doi.org/10.1086/505351
11. Lasfar A, Zloza A, Cohen-Solal KA. IFN-lambda therapy: current status and future perspectives. Drug Discov Today. 2016;21(1):167-71. DOI: https://doi.org/10.1016/j.drudis.2015.10.021
12. Thomas H, Foster G, Platis D. Mechanisms of action of interferon and nucleoside analogues. J Hepatol. 2003;39:93-8. DOI: https://doi.org/10.1016/s0168-8278(03)00207-1
13. Leviyang S. Interferon stimulated binding of ISRE is cell type specific and is predicted by homeostatic chromatin state. Cytokine X. 2021;3(4):100056. DOI: https://doi.org/10.1016/j.cytox.2021.100056
14. Reddy U, Krzystolik M. Antiangiogenic therapy with interferon alfa for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews. 2006. DOI: https://doi.org/10.1002/14651858.CD005138.pub2
15. Arús E, Pérez N, Parrilla M, Dominguez C. Efecto antifibrótico del interefrón alfa 2b recombinante en la cirrosis hepática por virus B o C. Rev Cuban Med. 2005 [acceso 20/09/2024];44:3-4. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232005000400008
16. Younes HM, Amsden BG. Interferon‐γ Therapy: Evaluation of Routes of Administration and Delivery Systems. J Pharm Sci. 2002;91(1):2-17. DOI: https://doi.org/10.1002/jps.10007
17. Kaur S, Mahajan B. Interferons. Indian J Dermatol Venereol Leprol. 2015;81(1):51. DOI: https://doi.org/10.4103/0378-6323.148570
18. Costa MB, Picon PD, Sander GB, Cuni HN, Silva CV, Meireles RP, et al. Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers. BMC Pharmacol Toxicol. 2018;19(1):1. DOI: https://doi.org/10.1186/s40360-017-0192-z
19. Arnaud P. Les différents interférons : Pharmacologie, mécanismes d’action, tolérance et effets secondaires. Rev Med Interne. 2002;23:449S-58S. DOI: https://doi.org/10.1016/S0248-8663(02)00659-8
20. Sleijfer S, Bannink M, Gool AR, Kruit WHJ, Stoter G. Side Effects of Interferon-α Therapy. Pharmacy World & Science. 2005;27(6):423-31. DOI: https://doi.org/10.1007/s11096-005-1319-7
21. Torkildsen Ø, Myhr KM, Bø L. Disease‐modifying treatments for multiple sclerosis – a review of approved medications. Eur J Neurol. 2016;23(S1):18-27. DOI: https://doi.org/10.1111/ene.12883
22. Grassegger A, Hopfl R. Significance of the cytokine interferon gamma in clinical dermatology. Clin Exp Dermatol. 2004;29(6):584-8. DOI: https://doi.org/10.1111/j.1365-2230.2004.01652.x
23. Muse ME, Stiff KM, Glines KR, Cline A, Feldman SR. A review of intralesional wart therapy. Dermatol Online J. 2020 [acceso 24/09/2024];26(3). Disponible en: https://pubmed.ncbi.nlm.nih.gov/32609439/
24. Sethi TK, Montanari F, Foss F, Reddy N. How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome. Br J Haematol. 2021;195(3):352-64. DOI: https://doi.org/10.1111/bjh.17458
25. Latzka J, Assaf C, Bagot M, Cozzio A, Dummer R, Guenova E, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023. Eur J Cancer. 2023 [acceso 24/09/2024];195:113343. Disponible en: https://www.ejcancer.com/article/S0959-8049(23)00645-7/fulltext
26. Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. Eur J Cancer. 2022 [acceso 24/09/2024];170:256-84. Disponible en: https://www.ejcancer.com/article/S0959-8049(22)00228-3/fulltext
27. Asadullah K, Sterry W, Trefzer U. Cytokines: interleukin and interferon therapy in dermatology. Clin Exp Dermatol. 2002;27(7):578-84. DOI: https://doi.org/10.1046/j.1365-2230.2002.01144.x
28. Hanlon A, Kim J, Leffell DJ. Intralesional interferon alfa-2b for refractory, recurrent squamous cell carcinoma of the face. J Am Acad Dermatol. 2013;69(6):1070-2. DOI: https://doi.org/10.1016/j.jaad.2013.02.032
29. Esser S, Schöfer H, Hoffmann C, Claßen J, Kreuter A, Leiter U, et al. S1 Guidelines for the Kaposi Sarcoma. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2022;20(6):892-904. DOI: https://doi.org/10.1111/ddg.14788
30. Satterfield KR, Chambers CB. Current treatment and management of infantile hemangiomas. Surv Ophthalmol. 2019;64(5):608–18. DOI: https://doi.org/10.1016/j.survophthal.2019.02.005
31. Pardanani A. Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management. Am J Hematol. 2021;96(4):508-25. DOI: https://doi.org/10.1002/ajh.26118
32. Karadag O, Bolek EC. Management of Behcet’s syndrome. Rheumatology. 2020;59(Suppl:3):iii108-17. DOI: https://doi.org/10.1093/rheumatology/keaa086
33. Westfechtel L, Werner RN, Dressler C, Gaskins M, Nast A. Adjuvant treatment of anogenital warts with systemic interferon: a systematic review and meta-analysis. Sex Transm Infect. 2018;94(1):21-9. DOI: https://doi.org/10.1136/sextrans-2017-053150
34. Low-Calle AM, Prada-Arismendy J, Castellanos JE. Study of interferon-β antiviral activity against Herpes simplex virus type 1 in neuron-enriched trigeminal ganglia cultures. Virus Res. 2014;180:49-58. DOI: https://doi.org/10.1016/j.virusres.2013.12.022
35. Grassegger A, Hopfl R. Significance of the cytokine interferon gamma in clinical dermatology. Clin Exp Dermatol. 2004;29(6):584-8. DOI: https://doi.org/10.1111/j.1365-2230.2004.01652.x
36. Chang TT, Stevens SR. Atopic Dermatitis. Am J Clin Dermatol. 2002;3(3):175-83. DOI: https://doi.org/10.2165/00128071-200203030-00004
37. Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, Dréno B, et al. Practical guidelines for the management of interferon‐α‐2b side effects in patients receiving adjuvant treatment for melanoma. Cancer. 2008;112(5):982-94. DOI: https://doi.org/10.1002/cncr.23251
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 alberto cesar castillo oliva
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The Cuban Journal of Medicine protects the author's patrimonial rights. However, it is licensed under a Creative Commons Licensehttps://creativecommons.org/licenses/by-nc/4.0/deed.es_ES which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided that the primary source of publication is duly cited. The author always retains his moral rights.
You are free to:
- Share - copy and redistribute the material in any medium or format.
- Adapt - remix, transform and build upon the material
- The license cannot revoke these freedoms as long as you follow the terms of the license.
Under the following terms:
- Attribution - You must give proper credit, provide a link to the license, and indicate if changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is supported by the licensor.
- Non-Commercial Purpose- You may not make use of the material for commercial purposes.
- No Additional Restrictions - You may not apply legal terms or technological measures that legally restrict others from making any use permitted by the license.
